C. difficile infection ⭐

c-difficile · high-yield

← back to Gastroenterology & Hepatology

Summary

IDSA/SHEA 2021 focused update on management of Clostridioides difficile infection (CDI) in adults, addressing the use of fidaxomicin and bezlotoxumab. Fidaxomicin is now preferred over vancomycin for both initial and recurrent CDI episodes (conditional recommendations), reflecting lower recurrence rates. Bezlotoxumab is suggested as an adjunct to standard-of-care antibiotics for patients with recurrent CDI within the past 6 months, especially those with additional risk factors for recurrence.

Current guideline: IDSA/SHEA 2021 Focused Update · download Anki sub-deck

Versions